Sat October 5, 2019 Old Greenwich, CT US 06870 Directions
Events
Walk - $25/Adult, $10 for 10yo-21yo

2.5 Mile Walk at Tod's Point - 10yo to Adult (Under 14 must be w/Adult)

$25 8:00AM EDT - 12:00PM EDT Registration ends October 4, 2019 at 5:00pm EDT
Walk - Under 10yo - FREE

2.5 Mile Walk at Tod's Point - Under 10yo (must be w/Adult)

$0 8:00AM EDT - 12:00PM EDT Registration ends October 4, 2019 at 5:00pm EDT
Can't join us that day...

Be a Virtual Walker

$25 Registration ends October 4, 2019 at 11:59pm EDT
Race Website

Additional race information can be found at https://danasangels.org/2nd-dart-to-the-finish-walk-sat-oct-5-2019.

Place
South Concession - Tod's Point
Tod's Driftway
Old Greenwich, CT US 06870
Description

Gather your friends and family and join us for an invigorating 2.5 mile walk around beautiful Tod’s Point in Old Greenwich, and help us raise much needed funds to find a cure for Niemann-Pick type C disease.

All are welcome. Park fees are included in your walk registration for Greenwich residents and non-residents.

Sorry, no dogs allowed at Tod’s Point by the Town of Greenwich at this time of year.

Race Contact Info

If you have any questions about this race, click the button below.

Questions?
BEAUTIFUL TOD'S POINT, OLD GREENWICH, CT

Image

About Dana's Angels Research Trust

Dana’s Angels Research Trust is a non-profit organization that funds research into a rare disease, Niemann-Pick type C (NPC), a fatal, cholesterol-storage disease affecting children.  Two of the Marella’s four children, Dana and Andrew, were afflicted by NPC.  Most children who suffer from NPC die in their early teens, but DART has helped change that fate.  As an all-volunteer organization, over 95% of the funds expended are channeled directly into supporting pivotal NPC research; research that may also help millions of people suffering from HIV/Aids, heart disease, stroke, Alzheimer’s disease  and other disorders that appear to be related to cholesterol.

Sadly, the Marella’s daughter, Dana, 19, passed away in the Summer of 2013.  When Dana died, she was confined to a wheelchair, no longer talked, suffered from frequent pneumonia and required constant care, but she always had a smile on her face and was an inspiration to many, both here and around the world.  The Marella’s youngest child, Andrew, 19, is relatively stable right now, although with the passing of his sister, Andrew struggles with seizures.  Andrew has benefited from two experimental medications and is a patient in the latest drug trial that started at the NIH and is now being taken forward by Mallinckrodt Pharmaceuticals, all due in large part to the supporters of DART.

About Niemann-Pick type C Disease and its Research Benefits

Niemann-Pick type C (NPC) is a rare genetic disease.  But there is strong interest in studying NPC from researchers in many fields because of its connection to cholesterol metabolism.  Research has shown that studying NPC may unlock the mysteries related to more common diseases affecting millions.

HIV/AIDS and Ebola:  The NPC protein is critical for the normal trafficking of cholesterol in all of the cells in our bodies.  Research shows that chemical creation of the NPC defect in diseases like HIV and Ebola results in drastically reduced infection, indicating that the NPC protein associated with cholesterol trafficking is required for infection.

Alzheimer’s:  Alzheimer’s and NPC are progressive neurological diseases with similar effects on the brain.  Recent studies comparing the two diseases discovered that Alzheimer’s is closely tied to a failure in cholesterol metabolism – the very process that is central to NPC.

Heart Disease and Stroke:  We all know that high cholesterol is the main cause of heart disease and stroke.  But until the gene that causes NPC was discovered, researchers had few opportunities to identify the complex processes that regulate cholesterol.  How does the body know if it has too much cholesterol or too little?  NPC research is beginning to provide answers.

Facebook

Like this page and invite your friends on Facebook.